Skip to Main Content

Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.

Conditions

Asthma

Phase III

What is the purpose of this trial?

This study aims to determine the efficacy and safety of QAW039 (Dose 1 and Dose 2), compared with placebo, when added to GINA steps 4 and 5 standard-of- care (SoC) asthma therapy (GINA 2015) in each of the groups (patients with severe asthma and high eosinophil counts and all patients with severe asthma).

  • Trial with
    Novartis Pharmaceuticals
  • Start Date
    07/31/2018
  • End Date
    10/16/2019
Trial Image

For more information about this study, contact:

Terri-Dawn Levesh

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    09/18/2018
  • Study HIC
    #2000023028